Plasma total homocysteine in the active stage of ulcerative colitis

Józef Drzewoski1, Anita Gasiorowska, Ewa Małecka-Panas

  • 1Department of Gastroenterology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.

Insights

Elevated total plasma homocysteine (tHcy) is linked to active ulcerative colitis (UC) and disease recurrence. This increase, observed even with normal folate levels, may enhance blood clotting in UC patients.

Area of Science:

  • Gastroenterology
  • Clinical Biochemistry
  • Hematology

Background:

  • Ulcerative colitis (UC) is associated with an increased risk of thromboembolism.
  • Elevated total plasma homocysteine (tHcy) has been observed in UC patients, but its correlation with disease activity was unclear.

Purpose of the Study:

  • To investigate the relationship between total plasma homocysteine (tHcy) levels and the activity and recurrence of ulcerative colitis (UC).
  • To assess the influence of folate and vitamin B12 status on tHcy levels in UC patients.
  • To examine the association between tHcy and coagulation parameters in UC.

Main Methods:

  • A case-control study involving 30 UC patients (15 active, 15 remission) and 21 healthy controls.
  • Measurement of total plasma homocysteine (tHcy), serum folate, and vitamin B12 levels.
  • Assessment of selected coagulation parameters including platelet count, fibrinogen, and D-dimer.

Main Results:

  • Mean tHcy was significantly higher in UC patients (10.8 +/- 3.1 mmol/L) compared to controls (6.8 +/- 2.5 mmol/L).
  • Patients with active UC exhibited higher tHcy (11.2 +/- 3.5 mmol/L) than those in remission (9.0 +/- 2.3 mmol/L).
  • Higher tHcy levels correlated with disease duration and recurrence frequency (> or =4 recurrences). Active disease also showed elevated platelet count, fibrinogen, and D-dimer.

Conclusions:

  • Ulcerative colitis is associated with elevated tHcy, particularly in active and recurrent disease stages.
  • Normal folate status does not prevent tHcy elevation in UC.
  • Elevated tHcy may contribute to a procoagulant state in UC patients.
Abstract

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...